Bausch Health Companies Inc.
BHCDrug Manufacturers - Specialty & Generic
$8.20−7.97%As of Oct 30vs prior close
- Market cap
- $3.1B
- P/E (TTM)
- –
- From 52W high
- −7.97%
- EPS (LTM)
- -$2.29
- Revenue (LTM)
- $11.1B
- Net margin
- -7.57%
Nomior Score
39
Emerging BreakoutSpeculativeBottom 27% of the scored universe
Growth—
Quality48
Value54
Momentum33
Resilience36
Growth
+0.66%revenue a year over 9 fiscal years
FY16 $9.7BLTM $11.1B
Connections
Revenue to profitQ3 FY26
15% of revenue became net profit, up 8 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $2.94 billion
- Net income
- $436 million
- Diluted EPS
- $1.15
- Adjusted EPS
- $1.77
Revenue rose in the quarter across most segments, led by the Salix segment and Bausch + Lomb, and profit improved sharply from the prior-year period. The company raised its full-year guidance for revenue, adjusted EBITDA and adjusted cash flows from operations excluding Bausch + Lomb.